Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 TrialYuqin Song, Xin Du, Yue-Rong Shuang et al.|Advances in Therapy|2021Cited by 19
Asymptomatic multicentric Castleman disease: a potential early stage of idiopathic MCDLu Zhang, Li J, Qinhua Liu et al.|Blood Advances|2024Cited by 6